Effect of Neuronavigated Theta-Burst Transcranial Magnetic Stimulation (TBS) for Early Alzheimer's Disease
Reason given: The study was terminated due to funding constraints and resource limitations that made further recruitment and continuation unfeasible.
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
Trial details
- Who runs it
- Anhui Medical University
- Trial code
- NCT06524817
- Record updated
- 1 April 2025
- Original description
Comparison of the therapeutic effects of two neuronavigated theta-pulse transcranial magnetic stimulation in patients with Alzheimer's disease and their underlying neural mechanismsRead full original descriptionShow less
Comparison of the therapeutic effects of two neuronavigated theta-pulse transcranial magnetic stimulation in patients with Alzheimer's disease and their underlying neural mechanisms
Inclusion: Subject diagnosed with early Alzheimer's disease or related diseases according to NINCDS-ACDRADA criteria; Subjects must have a MMSE score between 15 and 27,indicating mild cognitive impairment or dementia; CDR score ≤ 1; Subject under treatment by IAChE for at least 3 months; psychotropic treatments are tolerated if they were administered and unchanged for at least 3 months.
Exclusion: Implanted pacemaker,medication pump,vagal stimulator,deep brain stimulator; Any history or clinical signs of other severe psychiatric illnesses (like major depression,psychosis or obsessive compulsive disorder); History of head injury,stroke,or other neurologic disease; History of seizures or unexplained loss of consciousness; Family history of medication refractory epilepsy; History of substance abuse within the last 6 months; CDR > 1; Organic brain defects on T1 or T2 images.